When was Inversago Pharma founded?

Inversago Pharma was founded in 2015 and raised its 1st funding round 3 years after it was founded.

Where is Inversago Pharma located?

Inversago Pharma is headquartered in Montreal, Canada. It is registered at 1019 Karsh, Ottawa.

Who is the current CEO of Inversago Pharma?

Maxime Ranger of Inversago Pharma.

Which legal entities is Inversago Pharma associated with?

Inversago Pharma is associated with Noibu Technologies Inc..

Is Inversago Pharma a funded company?

Inversago Pharma is a funded company, having raised a total of $115M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 25, 2018.

When was the latest funding round of Inversago Pharma?

Inversago Pharma's latest funding was a $***** Series C round on Oct 17, 2022, with participation from 8 investors. Its primary sector is Cannabis HealthTech. Globally, the Cannabis HealthTech sector has seen $126M in funding in 2026 to date.

Where does Inversago Pharma rank among its competitors?

Inversago Pharma ranks 1st amongst 5 active competitors, of which 3 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Flavocure Biotech, which secured $215K in Feb, 2025.

Who are the top competitors of Inversago Pharma?

Inversago Pharma's top competitors include Flavocure Biotech, Pascal Biosciences and Cannova Medical. Among them, Flavocure Biotech secured the most recent funding round in February, 2025.

Inversago Pharma - 2026 Company Profile, Team, Funding & Competitors

Company Details

Inversago Pharma (formerly GIcare Pharma) is focused on developing peripheral cannabinoid (CB1) receptor antagonist/inverse agonist for the treatment of metabolic diseases such as obesity, insulin resistance, and liver fibrosis. Its drug INV-101 (Inverse agonist of peripheral CB1) under phase-1.

Website: inversago.com
Social
Email ID: *****@inversago.com
Part Of
Registered Address: 1019 Karsh, Ottawa

Key Metrics

Founded Year

2015

Location

Montreal, Canada

Stage

Series C

Total Funding

$115M in 3 rounds

Latest Funding Round

Series C, Oct 17, 2022, $*****

Investors

AmorChem & 11 more

Ranked

1^st among 5 active competitors

Similar Companies

Cannova Medical & 1 more

View Inversago Pharma's full profile

Inversago Pharma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Noibu Technologies Inc. CIN: 10133353 , Canada, Active	Mar 07, 2017	-	-	-

Inversago Pharma has raised a total funding of $115M over 3 rounds. Its first funding round was on Jul 25, 2018. Its latest funding round was a Series C round on Oct 17, 2022 for $*****. 8 investors participated in its latest round. Inversago Pharma has 12 institutional investors.

Here is the list of recent funding rounds of Inversago Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 17, 2022	3987434	Series C	5948679	7020241	2999052	8608707
Sep 08, 2020	7682484	Series B	7971881	6297954	7717912	adMare BioInnovations & 1 more
Jul 25, 2018	7115254	Series A	5831512	9813532	Genesys Capital & 1 more	Accel-Rx & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Inversago Pharma's funding rounds and investors

The founders of Inversago Pharma is Maxime Ranger.

Here are the details of Inversago Pharma's key team members:

Maxime Ranger: Co-Founder & CEO of Inversago Pharma and founder of 3 other companies, Sema Thera, Mperia Therapeutics and gIcare Pharma.

Inversago Pharma's Board of Directors

Inversago Pharma's board has 5 active members. Mike Weider, Weston Gaddy, Robert Boukine, Kailin Noivo and Filip Slatinac are independent board members.

Here is the list of Inversago Pharma's board of directors:

Name	Type	Representing	Status	Duration
Mike Weider	Independent board member	-	Current	1y 7m
byqwabp	Independent board member	-	Current	9y 9m
phsurka	Independent board member	-	Current	6y 5m
ghvlykh	Independent board member	-	Current	6y 5m
cigeowp	Independent board member	-	Current	2y 8m

View details of Inversago Pharma's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Inversago Pharma include Flavocure Biotech, Pascal Biosciences and Cannova Medical. Here is the list of Top 10 competitors of Inversago Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Inversago Pharma 2015, Montreal (Canada), Series C	Peripheral cannabinoid (CB1) receptor antagonist/inverse agonist for the treatment of metabolic diseases	$115M	Amgen Business Development, New Enterprise Associates ... & 10 others	47/100
2nd	Flavocure Biotech 2014, Baltimore (United States), Series A	Developing next-generation oncology solutions inspired by nature for cancer treatment	$8.59M	Denning Growth Fund, Atlas Biotechnology	34/100
3rd	Pascal Biosciences 2013, Vancouver (Canada), Public	Developer of therapeutics from cannabis to treat cancer	-	NIH, HHS & 1 others	34/100
4th	Cannova Medical 2018, Rehovot (Israel), Series A	Provider of cannabis infused strips for consumers	-	Copland Road Capital, Biosphere Capital	21/100
5th	Cannaport Germany, Unfunded	Distributor of cannabinoid-containing extracts and cannabis flowers for medical purposes	-	-	16/100
6th	CBD International 2007, Valencia (Spain), Deadpooled	Provider of cannabis-derived therapeutic products	-	-	15/100
7th	The Cures 2018, Arsuf (Israel), Deadpooled	Developer of cannabinoids-based medicine for cancer therapy	-	-	15/100